<table>
<thead>
<tr>
<th>Title</th>
<th>Limbal Stem Cells and Corneal Epithelial Regeneration: Current Status and Prospectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Yan, L; Jiang, D; He, J; Wong, DSH; Lian, Q</td>
</tr>
<tr>
<td>Citation</td>
<td>Journal of Ocular Biology, 2014, v. 2 n. 1, p. article no. 10</td>
</tr>
<tr>
<td>Issued Date</td>
<td>2014</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10722/205576">http://hdl.handle.net/10722/205576</a></td>
</tr>
<tr>
<td>Rights</td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
Limbal Stem Cells and Corneal Epithelial Regeneration: Current Status and Prospectives

Keywords: Corneal structure; Limbal stem cell; Cell-based transplantation; Regeneration of corneal epithelium

Abstract

The clear cornea functions like a window that controls the entry of light for visual information and plays a protective role. The failure of appropriate repair following corneal injury results in loss of corneal function. The limbal region of the cornea is thought to serve as a unique reservoir of corneal epithelial stem cells where limbal stem cells (LSC) contributed to the regeneration of corneal epithelium. The deficiency of LSC (LSCD) results in the failed regeneration of corneal epithelium following injuries. In this review, we discuss the current knowledge of LSC and LSC-based transplantation for regeneration of corneal epithelium. We will first review the latest development of corneal structures. Next we will introduce the concept of LSC and the associated debates. Third, we will review different LSC-based transplantation methods for LSCD treatment and compare their advantages and disadvantages. Finally, we will discuss the improvements of regeneration of corneal epithelium.

Abbreviations

LSC: Limbal Stem Cell; LSCD: Limbal Stem Cell Deficiency; TAC: Transit Amplifying Cell; TDC: Terminally Differentiated Cell; CK: Cytokeratin; ABCG2: ATP-Binding Cassette Transporter G2; LEC: Limbal Epithelial Crypt; LC: Limbal Crypt; CX: Connexins; LEC: Limbal Epithelial Cell; ESC: Embryonic Stem Cell; HGEC: Conjunctival Epithelial Cell; BM-MSC: Bone Marrow-Derived Stem Cell; EpLiASC: Epidermal Adult Stem Cell; IPDPC: Immature Dental Pulp Stem Cell; HFSC: Hair Follicle-derived Stem Cell; MSC: Mesenchymal Stem Cells; AM: Amniotic Membrane; CLAU: Conjunctival Limbal Autograft; KLAL: Keratolimbal Allograft; HPCLK: Homologous Penetrating Central Limbo-Keratoplasty; SLET: Simple Limbal Epithelial Transplantation; lr-CLAL: Living-related Conjunctival Limbal Allografts

Introduction

The cornea is a transparent and avascular tissue, located at the front part of the eye. Its main function is to transmit and focus light to the correct position at the back of the eye for visual perception. Corneal tissue comprises three major layers: epithelium on the superficial surface, a stroma on the middle layer, and endothelium on the inner surface. The corneal epithelium sheds with stratified epithelial cells, and is thought to be replaced by stem cells located at the narrow edge of the cornea, in a region known as the limbus. The limbal region of the cornea provides a unique reservoir of corneal epithelial stem cells: limbal stem cells (LSC) are thought to be the main source for the regeneration of corneal epithelium following injury. A deficiency of limbal stem cells (LSCD) results in failure of corneal regeneration following injury, with consequent poor repair and ultimately loss of corneal transparency and subsequent blindness. In the past few decades, intensive research has focused on corneal stem cells as a source of regenerative cell-based therapy. This review summarizes the current knowledge of corneal epithelial stem cells and LSC-based transplantation in the regeneration of corneal epithelium. We will first review old and new information about the corneal structure. Second, we will discuss the current concept of LSCs; third, we will review studies of LSC-based transplantation and their advantages and disadvantages. Finally, we will discuss the future applications of LSCs.

Corneal Structure: Old and New Discoveries

As the window of the eye, the healthy cornea remains completely transparent and plays a major role in visual information. The clear cornea covers the front of the eye and is surrounded by the outer conjunctiva and inner sclera. These enclosing structures maintain the eyeball’s globe shape and protect the internal functional content.

The crucial function of vision is achieved by the highly specialized corneal structure, previously described as comprising five layers: epithelium, Bowman’s layer, stroma, Descemet’s membrane and endothelium. Transparency of the cornea is essential for clear vision and is achieved by a smooth epithelium with no encroachment of conjunctival cells. The transparency of the cornea also is associated with the absence of vasculature, uniformly spaced collagen fibers, a functional endothelium that regulates corneal hydration and the production of crystalline proteins by keratocytes in the stroma [1,2].

The smooth epithelium is the uppermost part of the whole tissue, providing a non-keratinized, stratified squamous layer. Differentiated squamous cells present microvilli (finger-like projections) and microvilli, with a glycolcalyx scaffold coating the surface. These components provide the structural framework to support and bind a complex of related factors, including tears, mucus, immunoglobulins and compact junctions between the epithelial cells, and constitute a protective barrier against invasion by infection [3]. During normal
Blinking, dead squamous cells are sloughed from the corneal epithelium. The corneal epithelium is subject to a constant cycle of cell renewal approximately every 9-12 months [4]. Epithelial cell loss from the corneal surface was defined in the "X, Y, Z hypothesis" by Thoft and Friend in 1983 [5]. The naturally desquamated epithelial cells (Z) are constantly replaced by proliferating and dividing cells at the basal epithelium (X), and cells which can migrate to the centre from the periphery (Y).

\[ X + Y = Z \]

Thus, migration occurs centripetally and circumferentially from the limbus and vertically from the basal layer forwards. Although the hypothesis is still questionable, there is a number of evidence to support this original observation. Remarkably, the animal study data supported the clinical results in LSCD patients [6-10].

The Bowman's layer is acellular and composed of collagen fibrils, lying between the epithelium and stroma as a separate entity from the subepithelial basement membrane. This layer may be a visible indicator of ongoing stromal-epithelial interactions in the human. When stromal-epithelial interactions are disturbed in diseases, the Bowman layer is commonly broken up [11]. The stroma, which constitutes up to 90% of the thickness of the cornea, is made up of bundles of regular spatial, near-uniformly thick connective collagen type I and IV fibers. The fibers are produced by keratocytes and embedded by an extracellular matrix. Stromal-epithelial interactions are bi-directional communications mediated by soluble cytokines during development, homeostasis, and wound healing in organs. The stromal-epithelial interactions in the cornea are regulated by hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF). HGF and KGF are released by the keratocytes to modulate physiologic functions of epithelial cells, like proliferation, motility and differentiation. The epithelial to stromal interactions are also modulated by interleukin-1 (IL-1) and soluble Fas ligand, which are produced by corneal epithelial cells following injury. IL-1 dominantly regulates corneal wound healing through functions such as matrix metalloproteinase, HGF and KGF production, and apoptosis of keratocytes. The Fas/Fas ligand system primarily contributes to the immune privileged status of the cornea. Other cytokines, including epithelium growth factor from keratocytes and tumor necrosis factor α from epithelial cells, also play the important roles in the interactions [12]. Besides the corneal epithelial cells [13], and keratocytes in the supporting stroma [14], there are another two sources supplying multiple cytokines in the maintenance and healing of the cornea: the adjacent tear film [15], the aqueous humor [16].

The Descemet's membrane, which can regenerate following injury, serves as the modified basement membrane between the stroma and the endothelium. The endothelium is the innermost, single hexagon-shape cell layer of the cornea. With a different origin, function and appearance to vascular endothelium, it governs the transport of nutrients and retains the slightly dehydrated state of the cornea [17]. Compared to some mammals such as rabbits, guinea pigs and cats, the human endothelium lacks a complete regenerative capacity through cellular division and subsequent migration, which is similar to the monkey's endothelium [18].

**Concept of Limbal Stem Cells and the Associated Debates**

**Limbus microenvironment**

The limbus is the border zone between the transparent cornea and...
the opaque ‘whites of the eye’. Various studies related to the limbal microenvironment suggest that this special region participates in maintaining “stemness.” Histologically, limbal epithelium is unique; it consists of more than 10 cell layers and is the thickest among the three as compared to 1-2 cell layers for the conjunctival epithelium and 4-6 cell layers for the corneal epithelium [19] (Figure 1). In humans, a regional specialization of the epithelial structure in the limbus was first speculated by Davanger and Evensen, and called ‘palisades of Vogt’ [20]. This structure is rich in melanin content, which can protect LSC from UV damage. The basal cells of this structure, some of which are the presumed LSC, are tightly attached to the underlying basement membrane and have a rich network of blood supply through the characterized radially oriented fibrovascular ridges. The ridges are more common in the superior and inferior quadrants around the eye. The palisades of Vogt are composed of stromal invaginations, allowing access to chemical signals that diffuse from the underlying vascular network [21]. In 1986, Schermer A et al. presented a 64K keratin, cytokeratin 3 (CK3), was positively expressed in the limbal basal layer, and led strong support of LSC location in the limbus [22]. In 1989, George Cotsarelis et al. identified a subpopulation of slow-cycling limbal basal cells using 3H-thymidine labeling, which shared a set of common features with various epithelial stem cells. In common with other adult somatic cells, LSCs are small in size, have a high nuclear to cytoplasmic ratio, and lack expression of differentiation markers. In the event of injury, the slow cycling LSCs become highly proliferative [23]. These putative LSCs simultaneously retain their capacity for self-renewal and maintain a constant cell number by giving rise to fast-dividing progenitor cells, termed transit amplifying cells (TAC) [24]. These TAC compose the majority of the proliferative cell population in the corneal/limbal epithelium, and can experience a limited number of divisions before turning into terminally (post-mitotic) differentiated cells (TDC) [22]. The process of TDC shedding from the ocular surface during normal wear and tear stimulates epithelial cell division, migration, and differentiation [1,25] (Figure 2A and 2B). The differences between the two progenitor cells, LSC and TAC, are various, such as the expression of some markers (see 2.2), pigment protection, cell cycle length, response to tumor promoter [23,26,27] cell size, and ex vivo expansion supported material [28].

The limbal microenvironment termed “LSC niche” is first proposed by Schofield in 1983 [29]. The niche serves as a ‘reservoir’ for harboring and supporting a small population of putative LSCs, as well as providing a barrier to excessive growth of conjunctival cells and invasion of blood vessels into the cornea. The conjunctival ingrowth of the cornea occurs when the protective function fails and stable immunity of the cornea is destroyed. Environmental factors of niche include the limbal extracellular matrix, particularly the basement membrane, cell-matrix interactions, and cell-cell contacts. The underlying limbal stroma with keratocytes and blood supply network also plays a role in this environment by releasing various soluble cytokines [30-32]. In 1989, Kolega J et al. found that the basement membrane component AE-27 expressed weakly in the limbal region, and correlated with negative staining for CK3 [33]. In 1995, Ljubimov et al. gave rise to the assumption that the heterogeneity of the limbal

**Figure 2:** (A) A diagram denoting the self-renew and proliferative capability of limbal stem cells (LSCs). LSCs give rise to transit amplifying cells (TACs) as well as LSCs. TACs become mature and divide into terminally (post-mitotic) differentiated cells (TDCs). (B) A demonstration showing the relationship between LSC and other neighboring cells. LSCs locate in the basal layer of the limbal epithelium. LSC-derived TACs locate from the peripheral cornea to the central cornea, and gradually fail to proliferation. TDCs progressively replace the desquamated corneal differentiated epithelial cells.
extracellular matrix might be partially responsible for the different cell phenotypes and proliferative behavior. The limbal basement membrane is composed of collagen IV (α1-2) chains and laminin (α1-3, β1-3, γ1-2) chains; whereas collagen type IV (α3-5) chains and laminin (α1 and 3, β1 and 3, γ1-2) chains are contained in the corneal basement membrane [34-36]. Along this line, Espana et al. found that the CK3-negative phenotype of the limbal basal cells is mediated through the limbal stroma/basement membrane complex [37]. Diverse studies collectively point out that the niche is crucial in regulating the self-renewal and fate decision of LSC, although the precise mechanism remains obscure. In 2005, compared to submerged culture, the results of limbal explants air-lifting culture suggested that epithelial-mesenchymal transition via the Wnt/β-catenin pathway influences the fate of limbal epithelial progenitor cells, between regeneration and fibrosis during wound healing when the stromal niche is activated [38].

**Evidence of LSC**

No single, definitive marker has yet been found to identify LSC despite numerous attempts. Nonetheless, the expression of a combination of ‘markers’ is used for identification and isolation of putative LSC, either positive (present) or negative (absent). Limbal basal cells lack differentiation markers such as CK3 that is present in all other layers of the corneal epithelium and the suprabasal layers of the limbal epithelium [22]. CK12 is also expressed in a similar pattern [39]. Involutrin is expressed in the corneal stratified squamous epithelium as a marker of differentiation [40]. Connexin 43 (CX43) is present in the corneal basal cells except that of the limbus for cell-cell communication by gap junctions. The lack of CX43 expression in stem cells helps protect them against damage affecting adjacent neighbors [41].

Although the limbus is acknowledged as the site of corneal epithelial stem cells, the well-defined anatomical niche for LSCs was not described until 2005. Dua’s group re-evaluated the systematic serial 5-7 mm sections of human corneoscleral segments obtained from cadaver donors, with the corneal epithelial marker CK14 and the "stem cell" marker ATP-binding cassette transporter G2 (ABCG2) [42]. These distinct anatomical extensions from the limbal palisades, which consist of a solid cord of CK14/ABCG2-positive cells extending along the basal cells of the limbus more than along the basal cells of the adjacent conjunctiva, revealed features of being a LSC niche. This identified structure was termed the limbal epithelial crypt or limbal crypt [43]. Thus far, besides humans and pigs, a limbal epithelial crypt has not been discovered in other species [44].

Yang et al. first demonstrated that transcription factor p63 was critical during epithelial development [45]. Initially, p63 was considered to be a specific LSC marker in human cornea [46]. However, later studies found that p63 was involved in normal development and carcinomas [47]. The preferential expression of ∆Np63α (the α isoform of N-terminal transactivation domain-negative p63) in activated human limbal basal layer suggested that ∆Np63α was the most specific marker for LSC [48,49]. In 2007, using confocal imaging, Shortt et al. first provided the evidence in vivo that the structures of the palisades of Vogt are only one facet of the limbal niche architecture, forming the lateral walls of the stromal structures that encircle limbal crypts. Meanwhile, consistent with the previous studies [40,48], the putative LSC markers ABCG2 and ∆Np63α were expressed only by limbal basal cells and not by the corneal epithelium [50].

N-Cadherin and CK15 are two other promising candidate LSC antigens that co-localize to clusters of progenitor-like cells in the limbus [51]. The cell cycle arrest transcription factor C/EBPβ has also been implicated in the regulation of LSC self-renewal [52] (Figure 1).

The dogma that limbal stem cells are the exclusive source of corneal epithelial cells has been recently challenged. In 2008, Majo et al. found that in both mice and young children, healthy central corneal epithelium could generate holoclones with characteristics of stem cells that can maintain the corneal epithelium, probably without acute participation from the limbal region [53]. Furthermore, Dua et al. discovered normal central islands of corneal epithelium in adult eyes with clinically total limbal stem cell deficiency (LSCD) [54]. These data demonstrate that some LSCs remain and contribute to maintenance of the central epithelium in a clinically invisible way, or that basal cells of the central surviving epithelium can independently maintain the central epithelium. Nonetheless, the location of stem cells in the ocular surface may be species- or age-specific [54]. Majo et al. proposed the hypothesis that LSC functions response to injury and are not concerned with normal wear and tear of the corneal epithelium [53]. This remains to be determined by advanced studies related to the long-accepted TAC hypothesis. In addition, Dua et al. questioned whether LSC would regenerate the corneal epithelium in acute participation when the healthy central corneal islands were destroyed [54]. The first indication of the presence of LSCs was the observation in a rabbit that melanin moved centripetally from the limbus towards a corneal epithelial defect [55]. Limbal LSC transplantation following the corneal epithelium injuries in clinical practices indicated a high success rate of corneal wound healing, further supporting the hypothesis of the location of LSCs [20,56-59].

**Limbal Stem Cell Deficiency and Treatment**

**Limbal stem cell deficiency**

LSCD is characterized principally by damage or dysfunction of limbal stem cells with consequent invasion of conjunctival epithelium into the cornea [2]. The X or Y component of the X, Y, Z hypothesis is changed under such a pathologic condition, and induces failure of corneal homeostasis.

The etiology of LSCD is varied but primarily includes congenital disease, ocular trauma or disease (e.g. trachoma, pterygium), autoimmune disease (e.g. Stevens Johnson syndrome and ocular cicatricial pemphigoid), systemic disease (e.g. diabetes), chemical burn, ultraviolet or ionising radiation, iatrogenic injury and contact lens-related pathology.

The process of conjunctivalization is considered the hallmark of LSCD [60]. The other combined clinical signs are also involved, such as goblet cell infiltration, corneal neovascularization, and persistent epithelial defects and scarring. As a consequence, LSCD culminates in visual impairment and persistent pain in patients [61]. LSCD is classified as partial or total, and unilateral or bilateral [62]. If the pupillary area is covered by encroaching conjunctival epithelium, intervening action should be undertaken [63], as well as the indication from significant ocular pain.
Treatment of LSCD

A plentiful range of strategies to treat LSCD has been developed since 1940, when amniotic membrane (AM) was used in the first tissue-based procedure. Penetrating keratoplasty as the standard therapy of central corneal replacement is not available for LSCD, since restoration of the stem cell population is not involved [64], with the donor source and graft rejection as important limitations [19,65].

Current therapy of LSCD can be categorized using either cultured or non-cultured tissue or cell type for transplantation or alternative approaches without transplantation. In present review, we focus on the development of both cultured and non-cultured cell-based transplantation (Figure 3A and 3B).

In the first instance, conditions such as tear film deficiency, inflammation, lid abnormalities and corneal and conjunctival anesthesia should be investigated and addressed prior to surgery [66]. Use of cultured or non-cultured tissue and cell type should then be determined. Technically, the ideal method requires an easily accessible transplantation material, effective transplantation and stable clinical outcomes.

Cultured cell-based transplantation: In cultured LEC transplantation, LECs are expanded on substrate ex vivo from living or cadaver human cornea [67], and transplanted with or without the substrate onto the bare cornea that has been exposed by surgically removing the fibrovascular pannus (Table 1). Repeating this transplantation in the same eye can lead to higher final clinical success rate [68] and improvement in visual acuity [69]. The overall significant improvement rate of cultured LSC transplantation (according to the differently considerable criteria in different studies) was higher for autografts than for allografts [60,70,71]. The most common complications following transplantation included bleeding, inflammation, blepharitis and epitheliopathy. Less common was keratitis, residual fibrin, rejection of cultured LECs, corneal perforation, glaucoma, and infection [60,68,71-74]. Follow-up should continue for at least two years, especially since many complications are observed during the first year [68,69]. A benefit of this transplantation is that the risk of stem cell failure in the donor eye can be minimized via a small biopsy [75], with further opportunities to harvest LSCs [69,72]. Another advantage is the reduced risk of rejection of allografts compared with direct limbal tissue transplantation [76]. The major limitation is the high cost of stem cell procedures and high requirement of expertise. It remains unknown how cultured LSCs reconstruct the ocular surface. It is widely held that LECs may replace progenitor/stem cells, and/or revitalize dormant stem cells of the recipient by providing growth factors/chemotactic stimuli.

Much attention has recently focused on oral mucosal epithelial cells [72,77,78] in contrast to other cultured non-LSC cell sources. The neovascularization that occurs following oral cell transplantation may be diminished by anti-angiogenic therapy [79]. As another feasible cell source, conjunctival epithelial cells, have been applied in animal and human LSCD models in the same way as oral cells [80,81]. Other documented cultured cell types include embryonic stem cells.
bone marrow-derived mesenchymal stem cells (MSCs), epidermal epithelial cells, human immature dental pulp stem cells, hair follicle-derived stem cells, umbilical cord stem cells.

Non-cultured cell-based transplantation: A direct transplantation without requirements of cell culture procedures has been employed in various tissues (Table 2). Amniotic membrane (AM), the innermost layer of the placenta, serves broadly as an extracellular matrix for cell cultivation and a carrier for cultured cell transplantation. AM comprises a single layer of epithelium, a thick basement membrane and an avascular stroma and has been shown to support adhesion, migration, differentiation and proliferation of epithelial cells [97]. The dominant properties of AM substrate are low or no immunogenicity with anti-inflammatory, anti-angiogenic,

<table>
<thead>
<tr>
<th>Year (1st publication)</th>
<th>Cell/Tissue Type</th>
<th>Species</th>
<th>Method of Transplantation (host)</th>
<th>Outcomes</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>1997 limbal epithelial cells (LEC)</td>
<td>H Donor:</td>
<td>Autologous corneal epithelial sheets generated by serial cultivation of limbal cells cultivated from a 1 mm² biopsy sample taken from the patient’s healthy eye, with complete loss of the corneal-limbal surface in the injured eye.</td>
<td>Human damaged eye.</td>
<td>Follow-up for more than 2 years showed the stability of regenerated corneal epithelium and the striking improvement in patients' comfort and visual acuity.</td>
<td>[82]</td>
</tr>
<tr>
<td>2003 oral mucosal epithelial cells</td>
<td>R Donor:</td>
<td>Autologous oral mucosal biopsy specimens were cultivated for 3 weeks on a denuded AM carrier.</td>
<td>Rabbit conjunctivalized corneal surfaces at 3 to 4 weeks after total created corneal injury.</td>
<td>The cultivated oral epithelial sheets were very similar to normal corneal epithelium. Grafted corneas were clear and were all epithelialized 10 days after surgery.</td>
<td>[83]</td>
</tr>
<tr>
<td>2004 embryonic stem cells (ESC)</td>
<td>M Donor:</td>
<td>Epithelial progenitor cells derived from cultured mouse ESCs under optimal conditions.</td>
<td>Mouse corneas damaged by exposure to n-heptanol.</td>
<td>Cultured mouse ESCs induced epithelial progenitors induced successfully, with specific markers for corneal epithelial wound healing. Complete re-epithelialization of the corneal surface occurred within 24 hours of transplantation without any teratoma observed.</td>
<td>[84]</td>
</tr>
<tr>
<td>2006 conjunctival epithelial cells (HCjE)</td>
<td>R Donor:</td>
<td>HCjE cultivated on human AM to confluence and exposed to an air-liquid interface (air-lifted).</td>
<td>Rabbit corneas with total created injury.</td>
<td>The transplanted HCjE remained transparent, smooth, and without epithelial defects during the 2 weeks follow-up. The cultured cell sheets were similar in both morphology and molecular biology to normal corneal epithelium.</td>
<td>[85]</td>
</tr>
<tr>
<td>2006 bone marrow-derived stem cells (BM-MSC)</td>
<td>Ra Donor:</td>
<td>BM-MSCs from healthy donors were grown and expanded on AM.</td>
<td>Rat corneas with chemical burns after 7 days.</td>
<td>The data showed that BM-MSCs successfully reconstructed damaged corneal surface. The inhibition of inflammation and angiogenesis after transplantation of BM-MSCs was more related to the therapeutic effect than the epithelial differentiation from BM-MSCs.</td>
<td>[86]</td>
</tr>
<tr>
<td>2007 epidermal adult stem cells (EpiASC)</td>
<td>G Donor:</td>
<td>Cultivated goat EpiASC on denuded human AM.</td>
<td>Goats with total created LSCD.</td>
<td>The results showed repair of the damaged cornea.</td>
<td>[87]</td>
</tr>
<tr>
<td>2009 immature dental pulp stem cells (IDPSC)</td>
<td>R Donor:</td>
<td>Cultured human IDPSC</td>
<td>Rabbit corneas with total created LSCD after 30 days, accepted superficial keratectomy to remove the opaque tissue, and then got the transplantation.</td>
<td>The data suggested that hIDPSCs share similar characteristics to LSC and can reconstruct the eye surface.</td>
<td>[88]</td>
</tr>
<tr>
<td>2010 hair follicle-derived stem cells (HFSC)</td>
<td>M Donor:</td>
<td>Cultured mouse HFSCs on a fibrin carrier</td>
<td>Mouse corneas with created LSCD.</td>
<td>It was able to reconstruct the ocular surface in 80% of the transplanted animals.</td>
<td>[89]</td>
</tr>
<tr>
<td>2011 umbilical cord stem cells</td>
<td>R Donor:</td>
<td>Cultured human umbilical cord stem cells on a human AM.</td>
<td>Rabbit corneas with created LSCD.</td>
<td>Regeneration of a smooth, clear corneal surface with phenotypic expression of the normal corneal-specific epithelial markers.</td>
<td>[90]</td>
</tr>
<tr>
<td>2013 orbital fat-derived stem cells (OFSC)</td>
<td>H Donor:</td>
<td>Cultured OFSCs from healthy donors were resuspended in PBS.</td>
<td>Rabbit corneas with 70 or 100% chemical burns.</td>
<td>Topical administration of OFSCs promoted corneal re-epithelialization of both the limbal-sparing and limbal-involved corneal wounds, which is superior to that of the intralimbal injections.</td>
<td>[91]</td>
</tr>
</tbody>
</table>

*H: Human; R: Rabbit; Ra: Rat; G: Goat; M: Mice

Table 1: The list of the 1st publication using certain cell/tissue source related to cultured transplantation studies.
A combination of AM or lr-CLAL and KLAL is performed in some applications of AM transplantation. For example, AM extract and therapy [100]. Recent studies have nonetheless indicated far broader is not appropriate for total LSCD, but is feasible in partial LSCD and anti-scarring properties [98,99]. AM transplantation alone is not appropriate for total LSCD, but is feasible in partial LSCD therapy [100]. Recent studies have nonetheless indicated far broader applications of AM transplantation. For example, AM extract and non-cultured tissue combined with AM transplantation therapy [101,102].

Conjunctival limbal autograft (CLAU) [103] has limitations to be used for unilateral LSCD because limbal tissue attached to a conjunctival carrier from the healthy eye of the patient is required, and the transplantation process may increase the risk of LSCD in the healthy donor eye. In living-related conjunctival limbal allografts (lr-CLAL), the grafts from a living relative of the patient show a poorer long-term outcome than CLAU due to the unavoidable need for systemic immunosuppression [103-105]. Living donor allografts are nonetheless superior to cadaver allografts.

Based on the different choices of allografts, homologous penetrating central limbo-keratoplasty (HPCLK) is associated with a greater risk of immune rejection than conventional penetrating keratoplasty [106], while keratolimbal allograft (KLAL) involves the transplantation of cadaveric limbal tissue with its abundance of stem cells, together with a small rim of corneal and scleral tissue [103,104]. A combination of AM or lr-CLAL and KLAL is performed in some cases [107].

Simple limbal epithelial transplantation (SLET) has been shown to be valuable in the management of human LSCD. Compared with cultured LEC transplantation, this process can notably reduce the cost and period of cell culture, using very small amounts of biopsy tissue. Further clinical data are essential for the improvement of SLET, and a novel biodegradable alternative to AM is required.

### Challenges and Future Perspectives

Before corneal stem cell transplantation can be widely applied in clinical practice, a number of challenges need to be addressed. At present, most investigational protocols in corneal bioengineering and corneal stem cell therapy rely on the use of animal products and/ or allogeneic human cells and tissue. Such products raise potential risks, such as graft-versus-host disease, cataract, dry eye, glaucoma as well as animal transmitted diseases. More suitable material is urgently needed. A novel method of culturing expanded human limbal epithelial cells on human AM ex vivo has been developed using a cultured medium with autologous human serum as single growth supplement. Compared to the commonly used complex medium including FBS and other non-human derived products, omission of xenogenic ingredients may reduce the host immunogenicity of the transplanted tissue and also safeguard against the inter-species transmission [108]. Sequentially, above protocol was applied in clinical trial, and five in nine transplanted patients had obviously

---

**Table 2:** The list of the 1st publication using certain tissue source related to non-cultured transplantation studies.

<table>
<thead>
<tr>
<th>Year (1st publication)</th>
<th>Tissue Type</th>
<th>Species</th>
<th>Method of Transplantation (host)</th>
<th>Outcomes</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>1940</td>
<td>Amniotic membrane (AM)</td>
<td>H</td>
<td>N/A</td>
<td>N/A</td>
<td>[92]</td>
</tr>
<tr>
<td>1989</td>
<td>Conjunctival limbal autograft (CLAU)</td>
<td>H</td>
<td>Donor: Two free grafts of limbal tissue from the uninjured or less injured donor eye.</td>
<td>After not less than 6 months, the data showed stable ocular surface with improved visual acuity and epithelial recovery, which may be better for lamellar or penetrating keratoplasty later. No complications for donors.</td>
<td>[93]</td>
</tr>
<tr>
<td>1990</td>
<td>Keratolimbal allo graft (KLAL)</td>
<td>H</td>
<td>Donor: Corneal limbal epithelial cells. Recipient: Keratoepithelioplasty using allografts from donors.</td>
<td>For chronic ocular surface failure, it can help to establish a stable and clear optical surface after more than 4 months.</td>
<td>[94]</td>
</tr>
<tr>
<td>1999</td>
<td>Homologous penetrating central limbo-keratoplasty (HPCLK)</td>
<td>H</td>
<td>Donor: The eccentrically trephined unmatched grafts contained 40% limbus. Recipient: A surgical one-stage procedure was done in the central of the corneas. Systemic cyclosporin A (CSA) was administered for at least one year. Central clear graft survival was the main outcome criterion.</td>
<td>The failed grafts were mostly because of postoperative immunorejection. The left grafts had remained centrally clear for 12–41 months.</td>
<td>[95]</td>
</tr>
<tr>
<td>2012</td>
<td>Simple limbal epithelial transplantation (SLET)</td>
<td>H</td>
<td>Donor: A 2×2 mm strip of limbal tissue from the healthy eye was divided into 8-10 small pieces. Recipient: Patients with unilateral and total limbal stem cell deficiency following ocular surface burns underwent a single-stage procedure, with the tiny donor’s limbal evenly over an AM on the corneas.</td>
<td>It showed a completely epithelialised, avascular and stable corneal surface after 6 weeks, lasted for around 9 months. Visual acuity improved with no complications of donor eyes.</td>
<td>[96]</td>
</tr>
</tbody>
</table>

and anti-scarring properties [98,99]. AM transplantation alone is not appropriate for total LSCD, but is feasible in partial LSCD therapy [100]. Recent studies have nonetheless indicated far broader applications of AM transplantation. For example, AM extract and non-cultured tissue combined with AM transplantation therapy [101,102].

Conjunctival limbal autograft (CLAU) [103] has limitations to be used for unilateral LSCD because limbal tissue attached to a conjunctival carrier from the healthy eye of the patient is required, and the transplantation process may increase the risk of LSCD in the healthy donor eye. In living-related conjunctival limbal allografts (lr-CLAL), the grafts from a living relative of the patient show a poorer long-term outcome than CLAU due to the unavoidable need for systemic immunosuppression [103-105]. Living donor allografts are nonetheless superior to cadaver allografts.

Based on the different choices of allografts, homologous penetrating central limbo-keratoplasty (HPCLK) is associated with a greater risk of immune rejection than conventional penetrating keratoplasty [106], while keratolimbal allograft (KLAL) involves the transplantation of cadaveric limbal tissue with its abundance of stem cells, together with a small rim of corneal and scleral tissue [103,104]. A combination of AM or lr-CLAL and KLAL is performed in some cases [107].

Simple limbal epithelial transplantation (SLET) has been shown to be valuable in the management of human LSCD. Compared with cultured LEC transplantation, this process can notably reduce the cost and period of cell culture, using very small amounts of biopsy tissue. Further clinical data are essential for the improvement of SLET, and a novel biodegradable alternative to AM is required.

**Challenges and Future Perspectives**

Before corneal stem cell transplantation can be widely applied in clinical practice, a number of challenges need to be addressed. At present, most investigational protocols in corneal bioengineering and corneal stem cell therapy rely on the use of animal products and/ or allogeneic human cells and tissue. Such products raise potential risks, such as graft-versus-host disease, cataract, dry eye, glaucoma as well as animal transmitted diseases. More suitable material is urgently needed. A novel method of culturing expanded human limbal epithelial cells on human AM ex vivo has been developed using a cultured medium with autologous human serum as single growth supplement. Compared to the commonly used complex medium including FBS and other non-human derived products, omission of xenogenic ingredients may reduce the host immunogenicity of the transplanted tissue and also safeguard against the inter-species transmission [108]. Sequentially, above protocol was applied in clinical trial, and five in nine transplanted patients had obviously
achieved clinical improvement in 11 to 28 months follow-up [109]. From another point of view, the enzyme-related (e.g., trypsin-EDTA and dispase) dissociation or sequential incubation steps in cultured cell-based transplantation would induce DNA damage in the cell population destined for graft production. It is essential to maintain integrity of cellular and DNA repair mechanisms for proper cellular functioning including for long-term viability and proliferative potential. Therefore, it requires further optimization to improve ex vivo manipulating procedures and protocols to guarantee the quality of cell transplantation [110].

It is also important to systematically assess the advantages and disadvantages of cultured versus non-cultured limbal stem cell-based transplantation. It requires more understanding of molecular signals that constitute the limbal stem cell niche. Simultaneously, considering that the reported success rate differs widely between studies and depends on various parameters including the sources of tissue and the indications for surgery/concomitant ocular pathology, it is warranted for well-defined and stringent criteria to further illuminate and evaluate the transplantation methods and therapeutic outcomes among the prospective studies. Preferably, a greater number of patients with long enough follow-up data are necessary to assess the efficiency and superiority of the cell types and technique in LSCD therapy [109]. In addition, there is no consensus on the specific markers to identify limbal stem cells making between-study comparisons difficult.

In summary, although it is urgently needed to acquire more knowledge on appropriate potential cell sources, scaffold material, and growth elements, the progress in both basic research and clinical treatments indicate that there is great hope for stem cell-based therapies for regeneration of corneal epithelium in the near future.

References


ISSN: 2334-2838


Acknowledgements

This research is in part supported by HKU Seed Funding Programme for Basic Research Small Project Funding (2013111591150 to Q Lian), National Natural Science Grant of (SLET): a novel surgical technique for the treatment of unilateral limbal stem cell deficiency. Br J Ophthalmol 96: 931-934. This is in part supported by HKU Seed Funding Programme for Basic Research Small Project Funding (2013111591150 to Q Lian), National Natural Science Grant of (SLET): a novel surgical technique for the treatment of unilateral limbal stem cell deficiency. Br J Ophthalmol 96: 931-934.